Calderón VG, Salas CR, Sequeira QC

Idioma: Español
Referencias bibliográficas: 19
Paginas: 11-15
Archivo PDF: 101.41 Kb.

RESUMEN

La Leucoencefalopatía multifocal progresiva, a causa de la activación por la infección del virus JC, es una patología clásicamente asociada a factores de riesgo como la infección por VIH, las neoplasias hematológicas y los pacientes con inmunosupresión.
No obstante, recientemente, se ha podido identificar el Lupus Eritematoso Sistémico como un factor de riesgo para el desarrollo de dicha condición. La asociación de la Leucoencefalopatía Multifocal Progresiva con el Lupus Eritematoso Sistémico no parece encontrarse vinculada al tratamiento inmunosupresor sino a características inherentes a la enfermedad.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Tan C Koralnik I. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9(4):425-437.

2. Berger J Miller C Danaher R et al. Distribution and Quantity of Sites of John Cunningham Virus Persistence in Immunologically Healthy Patients. JAMA Neurol 2017;74(4):437.

3. Clifford D. Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis. JAMA Neurol 2011;68(9):1156.

4. Clifford D Nath A Cinque P et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol 2013;19(4):351-358.

5. Gomes da Silva M. JC virus: More than 40 years later with new implications. Braz J Infect Dis 2012;16(2):113-114.

6. Cortese I Muranski P Enose-Akahata Y et al. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. NEJM 2019;380(17):1597- 1605.

7. Vieira D Zanella D Avelino E et al. Progressive multifocal leukoencephalopathy in non-HIV patient. Dement Neuropsychol 2016;10(2):165-167.

8. Zhang Z Fan W Yang G et al. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2017;7:e012567.

9. Palazzo E Yahia S. Progressive multifocal leukoencephalopathy in autoimmune diseases. Joint Bone Spine 2012;79(4):351-355.

10. Bharat A Xie F Baddley J et al. Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res 2012;64(4):612-615.

11. Molloy E Calabrese L. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: Are patients with systemic lupus erythematosus at particular risk?. Autoimmun Rev 2008;8(2):144-146.

12. Molloy E Calabrese C Calabrese L. The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era. Rheum Dis Clin North Am 2017;43(1):95-109.

13. Henegar C Eudy A Kharat V Hill D Bennett D Haight B. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus 2016;25(6):617- 626.

14. Berger J. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 2017;12:59-63.

15. Pavlovic D Patel M Patera A Peterson I. T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy. Immunobiology 2018;223(6-7):508-517.

16. Talaat R Mohamed S Bassyouni I Raouf A. Th1/ Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine X 2015;72(2):146-153.

17. Nived O Bengtsson A Jönsen A Sturfelt G. Progressive multifocal leukoencephalopathy – the importance of early diagnosis illustrated in four cases. Lupus 2008;17(11):1036-1041.

18. Muftuoglu M, Olson A, Marin D et al. Allogeneic BK Virus–Specific T Cells for Progressive Multifocal Leukoencephalopathy. NEJM 2018;379(15):1443- 1451.

19. Alstadhaug K, Croughs T, Henriksen S et al. Treatment of Progressive Multifocal Leukoencephalopathy With Interleukin 7. JAMA Neurol 2014;71(8):1030.